WM (WM) Q1 2025 Earnings Call Transcript

WM reported first-quarter operating EBITDA up more than 12% year over year, with collection and disposal EBITDA up nearly 5% and recycling/renewable energy EBITDA up over 20%. Management reaffirmed 2025 guidance, including $7.45 billion to $7.65 billion of operating EBITDA and $2.675 billion to $2.775 billion of free cash flow, while highlighting $16 million of WM Healthcare Solutions synergies in the quarter and a path to $250 million annual run-rate synergies by 2027. The company also expects more than $500 million of solid waste acquisitions to close in 2025 and said tariff exposure is limited because most fleet and sustainability equipment has already been procured.

Analysis

WM is transitioning from a steady compounder into a self-help story with multiple, partially independent levers: pricing, automation, healthcare integration, and M&A. The important second-order effect is that these levers are mostly margin-accretive before they are growth-accretive, which reduces dependence on macro volume and makes the earnings path look unusually durable over the next 2-3 quarters. That matters because the market tends to underwrite waste names on “low growth” optics, while the actual driver here is operating leverage plus lower labor intensity.

The biggest hidden bull case is that Stericycle is not just an earnings add-on; it is a pricing architecture reset. If WM can push SG&A and internalization through a two-system setup without ERP integration risk blowing up service levels, the healthcare business could re-rate from a messy integration asset into a cleaner annuity stream with better cross-sell optionality. The market likely underestimates how quickly healthcare can become a margin bridge in 2H25 once contract renewal friction, fleet rationalization, and back-office standardization start compounding.

The main risks are timing and non-recurring drag: weather normalization can fade, but the easier comparison could mask any stumble in industrial volumes, commodity recycling, or the healthcare turnaround if execution slips into 2026. Tariff exposure is currently muted, but that only protects 2025; the real watch item is 2026 fleet and equipment inflation if supply chains reprice. Consistent with the company’s messaging, the near-term catalyst path is clear: sequential margin improvement in Q2/Q3, then possible upward revisions into the Investor Day if synergies and tuck-in closes are tracking ahead of plan.

Key Decisions for Investors

• Long WM into the June Investor Day on a 2-6 month horizon; risk/reward favors a higher multiple if Q2/Q3 margins continue to inflect and healthcare synergies accelerate. Use a stop on any evidence of service deterioration or healthcare integration slippage.
• Pair trade: long WM / short a higher-beta industrial services name with weaker pricing power and more cyclical volume exposure over the next 1-2 quarters. WM’s margin resilience should outperform if macro growth stays choppy.
• Sell downside protection or use a call spread on WM into the next earnings cycle if implied vol remains elevated. The thesis is that execution reduces downside tails while the stock still has a path to rerate on guidance credibility.
• If looking for a cleaner expression of the healthcare integration upside, buy WM on pullbacks and avoid chasing healthcare services pure-plays; WM’s cost synergies create a more durable earnings bridge than standalone growth narratives.
• Monitor 2026 capex/tariff language closely; if supply-chain inflation starts to creep into fleet replacement, reduce exposure or hedge with a short in a transport-equipment proxy.